Management

Friedhelm Blobel, Ph.D. has served as our President, Chief Executive Officer and as a Director since June 2006. From July 2000 to 2006, Dr. Blobel was President, CEO and a Director of Gryphon Therapeutics, Inc., a South San Francisco based biopharmaceutical company. Prior to joining Gryphon Therapeutics in July 2000, Dr. Blobel spent more than two decades as an executive with the Hoechst Group and the Boehringer Mannheim Group including responsibilities in the areas of diabetes and in vitro diagnostics. His roles at these companies included Group President of several product divisions, Chief Technology Officer and General Manager in Tokyo, Japan of a marketing and sales joint venture between Boehringer and Yamanouchi Pharmaceuticals (now Astellas Pharma, Inc.), Senior Vice President of Research and Development Diabetes and Patient Care in Mannheim, Germany as well as in Indianapolis, Indiana. Dr. Blobel earned his doctorate degree ("Dr.rer.nat."; a Ph.D. equivalent) with a dissertation in Biochemistry and Microbiology from the University of Hohenheim, Germany and holds an advanced degree in Chemistry from the University of Stuttgart, Germany.

Gary S. Titus has served as our Chief Financial Officer and Senior Vice President, Finance since December, 2008. Mr. Titus previously served as Senior Vice President of Finance and Chief Financial Officer at Kosan Biosciences, which was acquired by Bristol-Myers Squibb Company in May 2008, from September 2006 until September 2008. Mr. Titus joined Nuvelo, Inc. in January 2003 and served as Chief Financial Officer and Vice President from October 2005 to September 2006. Mr. Titus has also held positions at life sciences companies including Metabolex, Inc., Intrabiotics Pharmaceuticals, Inc., and LifeScan, Inc., a division of Johnson & Johnson. Mr. Titus holds a Bachelors of Science degree in Accounting from the University of South Florida and a Bachelor of Science degree in Finance from University of Florida and is a Certified Public Accountant. He also completed the Global BioExecutive Program at UC Berkeley's Haas School of Business and is a member of several professional organizations.

Hans P. Schmid is the President and Managing Director of SciClone Pharmaceuticals International, Ltd. and has been with SciClone since 2001. Mr. Schmid was Chief Financial Officer from December 1999 to April 2001 for Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), a specialty pharmaceutical company, and Senior Vice President, International Business Development from February 1997 to September 1999 for Oread, Inc., a contract pharmaceutical company. From 1985 to 1997 he worked at Syntex Corporation as Vice President of Finance and Administration for Pharmaceutical Operations Asia/Pacific region and at F. Hoffmann-LaRoche as Senior Vice President, Finance and Head of Administrative Services for Roche Bioscience. Previously he held financial and operational positions with Itel Corporation in Germany, Japan, England and the U.S. Mr. Schmid holds a Bachelors of Arts in General Business Administration from the Commercial Trade School, Lucerne, Switzerland.

Israel Rios, M.D. has served as our Senior Vice President, Medical Affairs and Chief Medical Officer since October 2005. In this capacity, he is responsible for the design and oversight of all clinical trials and the evaluation of new development candidates. From 2003 to 2005 he served as Vice President of Clinical Affairs for Dendreon Corporation, a biotechnology company. From 1993 to 2000, Dr. Rios was at Berlex Laboratories (the U.S. affiliate of Schering AG of Germany) most recently as Vice President of Oncology Development. From 1984 to 1993, Dr. Rios was Director of Anti-Infective Clinical Research at Marion Merrill Dow, Inc. where he directed the clinical development and helped manage the New Drug Application submissions of several anti-infective products. From 1978 to 1984, Dr. Rios held several positions at Bristol-Myers Squibb Company, most recently as Director of Clinical Research. Dr. Rios earned his M.D. degree at the Central University of Venezuela. He completed his internship and residency in internal medicine at Mount Sinai Hospital in Hartford, Connecticut, and his fellowship in infectious diseases at Hartford Hospital in Hartford, Connecticut.

Cynthia W. Tuthill, Ph.D., Senior Vice President, Scientific Affairs, and Chief Scientific Officer, has over 20 years of experience in the biotechnology and pharmaceutical industries. Dr. Tuthill has been with SciClone since October of 1991, where she is responsible for design and oversight of all nonclinical studies, leads several clinical development projects, and oversees both project management and manufacturing. Prior to joining SciClone, Dr. Tuthill was a senior product development scientist at Becton Dickinson Immunocytometry Systems, responsible for development of manufacturing methods, according to Good Manufacturing Processes, for new reagents for the assessment of viral diseases. From 1984 to 1990, she was a senior scientist at California Biotechnology, Inc. (now Scios, Inc.). At California Biotechnology she was project manager for several large heart disease therapeutic projects, as well as being responsible for analysis and purification of recombinant human proteins. Dr. Tuthill earned her undergraduate degree, summa cum laude, from the University of California, Berkeley, and her Ph.D. in protein biochemistry with highest honors from Harvard University.

Jeffery Lange has served as Vice President, Business Development since August 2008. Mr. Lange served most recently as Director, Business Development & Licensing Finance at Novartis in East Hanover, NJ where he was responsible for licensing, divestiture, co-marketing, and merger and acquisition valuation as part of a global negotiation team for Novartis Pharma General Medicines. Prior to that, Mr. Lange held various positions within Novartis including the Head of Strategic Financial Planning in Novartis' Pharma General Medicine group in Basel, Switzerland, and Manager of Business Development and Planning at Novartis Agribusiness. Earlier in his career, he held a variety of positions in planning and analysis, finance and accounting. Mr. Lange earned an M.B.A. with a specialization in Finance from the University of Chicago and a B.B.A. in Accounting from the University of Iowa.